nanotechnology platforms. Ascendia formulates products for injectable, oral, topical and transmucosal/ophthalmic routes of administration. The company has four technology platforms - EmulSol(r) for producing nano/micro-emulsions, AmorSol(r) for creating amorphous solid dispersions, NanoSol(r) for formulating nanoparticles, and LipidSol(r) for liposome and LNP formulations. Ascendia has a cGMP facility that scale-up formulations for tox/IND-enabling studies and also supply clinical trial materials in its aseptic and non-aseptic manufacturing suites.